Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production. 2017

Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
Department of Biochemistry, Juntendo University School of Medicine, Tokyo Japan.

Propofol is an intravenous anesthetic that produces its anesthetic effect, largely via the GABAA receptor in the CNS, and also reduces the N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced neutrophil respiratory burst. Because fMLP-stimulated neutrophils produce leukotriene (LT)B4, we examined the effect of propofol on LTB4 production in vivo and in vitro Cecal ligation and puncture surgery was performed in mice, with or without exposure to propofol. Propofol attenuated the production of 5-lipoxygenase (5-LOX)-related arachidonic acid (AA) derivatives in the peritoneal fluid. Also, in the in vitro experiments on fMLP-stimulated neutrophils and 5-LOX-transfected human embryonic kidney cells, propofol attenuated the production of 5-LOX-related AA derivatives. Based on these results, we hypothesized that propofol would directly affect 5-LOX function. Using meta-azi-propofol (AziPm), we photolabeled stable 5-LOX protein, which had been used to solve the X-ray crystallographic structure of 5-LOX, and examined the binding site(s) of propofol on 5-LOX. Two propofol binding pockets were identified near the active site of 5-LOX. Alanine scanning mutagenesis was performed for the residues of 5-LOX in the vicinity of propofol, and we evaluated the functional role of these pockets in LTB4 production. We demonstrated that these pockets were functionally important for 5-LOX activity. These two pockets can be used to explore a novel 5-LOX inhibitor in the future.-Okuno, T., Koutsogiannaki, S., Ohba, M., Chamberlain, M., Bu, W., Lin, F.-Y., Eckenhoff, R. G., Yokomizo T., Yuki, K. Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

UI MeSH Term Description Entries
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001094 Arachidonate 5-Lipoxygenase An enzyme that catalyzes the oxidation of arachidonic acid to yield 5-hydroperoxyarachidonate (5-HPETE) which is rapidly converted by a peroxidase to 5-hydroxy-6,8,11,14-eicosatetraenoate (5-HETE). The 5-hydroperoxides are preferentially formed in leukocytes. 5-Lipoxygenase,Arachidonic Acid 5-Lipoxygenase,LTA4 Synthase,Leukotriene A Synthase,Leukotriene A4 Synthase,Leukotriene A4 Synthetase,5 Lipoxygenase,5-Lipoxygenase, Arachidonate,5-Lipoxygenase, Arachidonic Acid,Arachidonate 5 Lipoxygenase,Arachidonic Acid 5 Lipoxygenase,Synthase, LTA4,Synthase, Leukotriene A,Synthase, Leukotriene A4,Synthetase, Leukotriene A4
D001095 Arachidonic Acids Eicosatetraenoic Acids,Acids, Arachidonic,Acids, Eicosatetraenoic

Related Publications

Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
January 2013, Journal of immunotoxicology,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
April 1997, The American journal of physiology,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
August 1994, Biological & pharmaceutical bulletin,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
September 1992, British journal of pharmacology,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
January 2008, The Journal of experimental medicine,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
July 1991, Biochemical and biophysical research communications,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
June 2018, Oncotarget,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
June 1996, FEBS letters,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
January 2014, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Toshiaki Okuno, and Sophia Koutsogiannaki, and Mai Ohba, and Matthew Chamberlain, and Weiming Bu, and Fu-Yan Lin, and Roderic G Eckenhoff, and Takehiko Yokomizo, and Koichi Yuki
January 1993, Journal of lipid mediators,
Copied contents to your clipboard!